Oscar Health (NYSE:OSCR) Rating Increased to Overweight at Barclays

Oscar Health (NYSE:OSCR) was upgraded by equities research analysts at Barclays from an “equal weight” rating to an “overweight” rating in a report issued on Wednesday, Marketbeat reports. The brokerage currently has a $35.00 price objective on the stock. Barclays‘s target price would suggest a potential upside of 28.90% from the company’s previous close.

A number of other brokerages have also recently issued reports on OSCR. Weiss Ratings reissued a “sell (d)” rating on shares of Oscar Health in a report on Tuesday, April 21st. UBS Group raised their target price on shares of Oscar Health from $15.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Robert W. Baird lifted their price target on Oscar Health from $15.00 to $19.00 and gave the stock a “neutral” rating in a research note on Thursday, May 7th. Wolfe Research initiated coverage on shares of Oscar Health in a report on Tuesday, May 5th. They issued a “peer perform” rating for the company. Finally, Zacks Research lowered Oscar Health from a “strong-buy” rating to a “hold” rating in a research note on Friday, June 5th. Three research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.78.

Oscar Health Stock Down 0.9%

Shares of NYSE:OSCR opened at $27.15 on Wednesday. The company has a market capitalization of $8.19 billion, a PE ratio of -46.02, a price-to-earnings-growth ratio of 1.92 and a beta of 2.37. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.11 and a quick ratio of 1.11. The business has a fifty day moving average price of $19.02 and a two-hundred day moving average price of $16.25. Oscar Health has a 1 year low of $10.69 and a 1 year high of $28.16.

Oscar Health (NYSE:OSCR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.96. Oscar Health had a negative net margin of 0.30% and a negative return on equity of 3.26%. The company had revenue of $4.65 billion during the quarter, compared to analyst estimates of $4.90 billion. During the same quarter last year, the business posted $0.92 EPS. Oscar Health’s quarterly revenue was up 52.6% compared to the same quarter last year. Analysts forecast that Oscar Health will post 0.47 earnings per share for the current year.

Insider Transactions at Oscar Health

In other Oscar Health news, CFO Richard Scott Blackley sold 31,683 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $21.94, for a total transaction of $695,125.02. Following the transaction, the chief financial officer directly owned 1,074,977 shares of the company’s stock, valued at approximately $23,584,995.38. The trade was a 2.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mario Schlosser sold 34,120 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $21.94, for a total transaction of $748,592.80. Following the completion of the transaction, the director owned 480,866 shares of the company’s stock, valued at $10,550,200.04. This trade represents a 6.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 189,660 shares of company stock worth $4,283,140. Corporate insiders own 25.11% of the company’s stock.

Institutional Trading of Oscar Health

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Oscar Health by 2.7% in the 4th quarter. Vanguard Group Inc. now owns 20,701,250 shares of the company’s stock valued at $297,477,000 after purchasing an additional 540,851 shares during the period. Geode Capital Management LLC boosted its stake in Oscar Health by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 4,798,313 shares of the company’s stock worth $68,964,000 after purchasing an additional 116,430 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Oscar Health by 1,097.8% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 237,882 shares of the company’s stock valued at $3,418,000 after buying an additional 218,022 shares during the last quarter. Farallon Capital Management LLC boosted its stake in Oscar Health by 146.5% during the 3rd quarter. Farallon Capital Management LLC now owns 3,639,000 shares of the company’s stock valued at $68,886,000 after purchasing an additional 2,163,000 shares during the last quarter. Finally, BIT Capital GmbH increased its holdings in Oscar Health by 545.0% in the 4th quarter. BIT Capital GmbH now owns 6,186,267 shares of the company’s stock worth $88,897,000 after buying an additional 5,227,152 shares in the last quarter. 75.70% of the stock is owned by institutional investors.

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.